Compare Stocks: ASBP, MIRA, UG, and VIRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$6.89 -2.1%	$6.20	$3.31 ▼ $1,050.36	$8.96M	0.11	364,294 shs	1,797 shs
MIRA MIRA Pharmaceuticals	$0.66 -1.7%	$0.94	$0.60 ▼ $2.45	$27.87M	1.54	133,522 shs	25,611 shs
UG United-Guardian	$7.15 +0.7%	$7.21	$5.58 ▼ $8.77	$32.83M	0.95	7,144 shs	640 shs
VIRI Virios Therapeutics	$1.79 +4.7%	$1.53	$0.13 ▼ $1.04	$34.47M	1.58	1.05 million shs	72,505 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	-2.63%	-2.76%	+13.37%	+26.16%	-98.39%
MIRA MIRA Pharmaceuticals	+9.95%	-19.62%	-28.56%	-32.50%	-57.01%
UG United-Guardian	-0.28%	-3.14%	-2.20%	+5.81%	-11.25%
VIRI Virios Therapeutics	+4.27%	+11.76%	+14.77%	+18.75%	-64.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$6.89 -2.1%	$6.20	$3.31 ▼ $1,050.36	$8.96M	0.11	364,294 shs	1,797 shs
MIRA MIRA Pharmaceuticals	$0.66 -1.7%	$0.94	$0.60 ▼ $2.45	$27.87M	1.54	133,522 shs	25,611 shs
UG United-Guardian	$7.15 +0.7%	$7.21	$5.58 ▼ $8.77	$32.83M	0.95	7,144 shs	640 shs
VIRI Virios Therapeutics	$1.79 +4.7%	$1.53	$0.13 ▼ $1.04	$34.47M	1.58	1.05 million shs	72,505 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	-2.63%	-2.76%	+13.37%	+26.16%	-98.39%
MIRA MIRA Pharmaceuticals	+9.95%	-19.62%	-28.56%	-32.50%	-57.01%
UG United-Guardian	-0.28%	-3.14%	-2.20%	+5.81%	-11.25%
VIRI Virios Therapeutics	+4.27%	+11.76%	+14.77%	+18.75%	-64.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	1.00	Sell	N/A	N/A
MIRA MIRA Pharmaceuticals	2.00	Hold	N/A	N/A
UG United-Guardian	2.00	Hold	N/A	N/A
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ASBP, MIRA, UG, and VIRI Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/21/2026	UG United-Guardian	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/17/2026	ASBP Aspire Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	UG United-Guardian	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
6/24/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	$10K	895.70	N/A	N/A	($54.19) per share	-0.13
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
UG United-Guardian	$10.55M	3.11	$0.48 per share	14.77	$2.44 per share	2.93
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$24.48M	-$116.67	N/A	N/A	N/A	N/A	N/A	-398.04%	N/A
MIRA MIRA Pharmaceuticals	-$10.44M	-$1.30	N/A	N/A	N/A	N/A	-140.82%	-135.01%	9/2/2026 (Estimated)
UG United-Guardian	$2.11M	$0.52	13.76	N/A	N/A	21.62%	21.40%	18.40%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest ASBP, MIRA, UG, and VIRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2026	Q1 2026	ASBP Aspire Biopharma	N/A	-$20.57	N/A	-$20.57	N/A	$0.03 million
5/14/2026	Q1 2026	MIRA MIRA Pharmaceuticals	N/A	-$0.03	N/A	-$0.03	N/A	N/A
5/8/2026	Q1 2026	UG United-Guardian	N/A	$0.18	N/A	$0.18	N/A	$2.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$0.60	8.45%	-5.11%	115.38%	1 Years
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest ASBP, MIRA, UG, and VIRI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/14/2026	UG United-Guardian		$0.30	8.19%	7/28/2026	7/28/2026	8/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	2.26	2.14
MIRA MIRA Pharmaceuticals	N/A	82.15	82.15
UG United-Guardian	N/A	8.05	7.15
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
MIRA MIRA Pharmaceuticals	35.16%
UG United-Guardian	23.16%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	5.80%
MIRA MIRA Pharmaceuticals	19.89%
UG United-Guardian	29.00%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	1.30 million	1.22 million	N/A
MIRA MIRA Pharmaceuticals	2	42.02 million	33.66 million	Not Optionable
UG United-Guardian	20	4.59 million	3.26 million	Not Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data

ASBP, MIRA, UG, and VIRI Headlines

Recent News About These Companies

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASBP, MIRA, UG, and VIRI Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$6.89 -0.15 (-2.13%)

As of 09:47 AM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

MIRA Pharmaceuticals NASDAQ:MIRA

$0.66 -0.01 (-1.73%)

As of 10:22 AM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

United-Guardian NASDAQ:UG

$7.15 +0.05 (+0.75%)

As of 09:30 AM Eastern

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

Virios Therapeutics NASDAQ:VIRI

$1.79 +0.08 (+4.68%)

As of 08/4/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASBP, MIRA, UG, and VIRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASBP, MIRA, UG, and VIRI Earnings

Compare Dividends

Latest ASBP, MIRA, UG, and VIRI Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASBP, MIRA, UG, and VIRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ASBP, MIRA, UG, and VIRI Company Descriptions

Aspire Biopharma NASDAQ:ASBP

MIRA Pharmaceuticals NASDAQ:MIRA

United-Guardian NASDAQ:UG

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools